| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection |
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
CERTAIN INFORMATION MARKED AS [* * *] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, Atea Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 59,742,819 shares of the Company’s common stock were present in person or represented... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-En... |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026 |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV |
| 20 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 20, 2025, Atea Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 74,981,407 shares of the Company’s common stock were present in person or represented... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV |
| 17 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
This letter (this “Agreement”) constitutes an agreement by and among (a) Atea Pharmaceuticals, Inc. (the “Company”) and (b) Bradley L. Radoff (and together with The Radoff Family Foundation, “Radoff”) and JEC II Associates, LLC (and toge... |
| 01 Apr 2025 |
8-K: Other Events
On March 31, 2025, Atea Pharmaceuticals, Inc. (the “Company” or “Atea”) received notice from Driver Opportunity Partners III withdrawing its prior notice that it intended to nominate J. Abbott R. Cooper to stand for election to the Compa... |
| 24 Mar 2025 |
8-K: Other Events
BOSTON, March 21, 2025 (5:54 PM ET) (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for ser... |
| 06 Mar 2025 |
8-K: Results of Operations and Financial Condition
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) |
| 24 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 20, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) elected Arthur Kirsch as a Class I director of the Company, effective immediately. |
| 14 Jan 2025 |
8-K: Results of Operations and Financial Condition
Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in Annual Net Sales |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24 |
| 07 Aug 2024 |
8-K: Results of Operations and Financial Condition
Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete |
| 21 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 21, 2024, Atea Pharmaceuticals, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 74,365,479 shares of common stock were present in person or represented by proxy at t... |
Loading...